Insider filing
Traded Dec 11, 2025 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 10, 2025 · Filed Nov 12, 2025
Serina Therapeutics's Chief Scientific Officer sold $27K of Serina Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$26,650
Shares × reported transaction price
91 days after results of Aug 11, 2025, 3 days before results of Nov 13, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $3.99 on Nov 10, 2025, within 3% of its 52-week low, after an 18% drop over the previous 30 trading days
52-week range $3.91 (Nov 7, 2025) to $6.31 (Apr 30, 2025), 3% of the way up, from 248 adjusted closes. 30 trading days earlier: $4.89 on Sep 29, 2025. Describes the past only, not a forecast
RSI 32, 24% under its 200-day average, 20% under its 50-day average, 37% below the 52-week high, 20-day volatility 63% a year, against the S&P 500: −29 points over 1 month, −33 points over 3 months, −46 points over 6 months
From the adjusted closes up to Nov 10, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.1% | −2.9% | −1.2% |
| 30 days | −23.7% | +1.3% | −25.0% |
| 90 days | −52.5% | +3.0% | −55.5% |
| 180 days | −58.4% | +9.8% | −68.3% |
| 365 days | −64.5% | +12.3% | −76.8% |
Past results only. Not a forecast.
Insider filing
Traded Dec 11, 2025 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Randall Moreadith (Chief Scientific Officer) sold ~$12K of Serina Therapeutics
Planned saleInsider filing
Traded Dec 11, 2025 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.